The 2021 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the Annual Meeting 2021. Please note that these abstract categories may or may not be used as Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is Thursday, November 19, 2020 (11:59 p.m. ET) and the late-breaking and clinical trials abstract submission deadline is Monday, January 11, 2021 (11:59 p.m. ET).

The AACR is committed to raising awareness about the enormous public health challenge of cancer health disparities and racial inequalities. We encourage you to view the relevant abstract subcategories and subclassifications in the listing below. Also, a new submission category, COVID-19 and Cancer, provides an opportunity to submit novel work in this timely and critically important area.
**ABSTRACT CATEGORIES (cont’d)**

**BSB02 Convergence Science and Systems Biology**
- Artificial intelligence and machine learning
- Integrative cancer biology
- Mathematical modeling
- Network biology
- Physical sciences and engineering
- Systems engineering
- Other

**TB Tumor Biology**

**TB01 Nonclinical Models of Cancer**
- 3-D and tissue recombinant models
- Developmental phenotypes of cancer genes
- Human-in-mouse models of human cancer
- Model organisms in drug discovery
- Mouse models of human cancer
- Noninvasive imaging in animal models
- Organoids
- Patient-derived xenograft models
- Zebrafish models of cancer
- Other animal and cell models of cancer
- Other

**TB02 Stem Cell Biology**
- Adult stem cells
- Cancer stem cells
- Developmental pathways in cancer
- Embryonic stem cells
- Stem cell markers
- Stem cells and regenerative medicine in oncology
- Other

**TB03 Tumor Adhesion**
- Cell adhesion and extracellular matrix
- Cell-cell adhesion
- Drug resistance
- Other

**TB04 Invasion and Metastasis**
- Actin cytoskeleton
- Biomarkers of metastasis
- Epithelial/mesenchymal transition (EMT and MET)
- Expression profiling of tumor progression and metastasis
- Genes that regulate migration and invasion
- Imaging of tumor progression and metastasis
- Invasion and migration
- Metastasis suppressor genes
- Metastasis-promoting genes
- Premetastatic niche
- Therapeutic metastasis prevention
- Other

**TB05 Angiogenesis**
- Angiogenesis and angiogenesis inhibitors
- Host-tumor interactions
- Molecular mechanisms of angiogenesis
- Novel pro- and antiangiogenic factors
- Tumor microcirculation and the microenvironment
- Other

**TB06 Tumor Microenvironment**
- Chemokines in the microenvironment
- Drug targets in the microenvironment
- Extracellular matrix and integrins
- Gene expression in the microenvironment
- Immune cells in the tumor microenvironment
- Immunity and the microenvironment
- Inflammatory cells as regulators of tumor growth
- Microbiome
- Organ-specific microenvironments
- Proteases and inhibitors in the microenvironment
- Tumor dormancy
- Tumor/stromal interactions
- Tumor-immune system interactions
- Other

**TB07 In Vivo Imaging**
(See also CL01: Translational Research – Molecular Biology in the Clinic)
- Advanced nanotechnology and imaging
- Application of imaging technology to the clinic
- Imaging in animal models
- Imaging of molecular and cellular events in the tumor microenvironment
- Imaging of molecular and cellular events in tumors and tumor cells
- Imaging the immune response
- Imaging tumor metabolism
- New targets for imaging
- Other

**TB08 Pediatric Cancer - Basic Science**
(See also CL02: Pediatric Cancer - Clinical Investigations; CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer)
- Developmental origins and drivers of pediatric cancer
- Pediatric cancer epigenomics and genomics
- Pediatric cancer models
- Pediatric cancer tumor microenvironment and tumor heterogeneity
- Other

**TB09 Radiation Science**
(See also CL07: Radiation Oncology; ET09: Preclinical Radiotherapeutics)
- Modulators of radiation response
- Photobiology/photodynamic therapy
- Radiation dose fractionation
- Radiation-activated signaling pathways
- Radiation-induced gene expression
- Radiation-induced resistance
- Radiobiology research
- Radioprotectors and radiosensitizers
- Other

**TB10 Tumor Evolution and Heterogeneity**
- Causes and consequences of tumor heterogeneity
- Complex adaptive systems
- Methods to measure tumor evolution and heterogeneity
- Other

**TB11 Carcinogenesis**
- Carcinogenesis: Chemical, environmental, and molecular
- Mutagenesis
- Tumor initiation and promotion
- Viral-induced carcinogenesis
- Other

**CH Cancer Chemistry**

**CH01 Drug Discovery, Design, and Delivery**
- Basic and applied nanotechnology and therapeutics
- Chemoinformatics, in silico screening, and computational methods
- Drug delivery
- Drug design
- High-throughput screening (assays and libraries)
- Lead identification
- Lead optimization
- Nanotechnology drug delivery
- Natural products
- Synthesis, metabolism, and disposition
- Other

**CH02 Structural and Chemical Biology**
- Chemical genetics and genomics
- Nanotechnology in chemical biology
- Small molecule, protein, and nucleic acid interactions
- Target identification, small molecule probes, and libraries
- X-ray and NMR structures
- Other

**CH03 Proteomics and Mass Spectrometry**
- Biological mass spectrometry and systems biology
- Proteomics and biomarker discovery
- Proteomics and signaling networks
- Other

**AACR.org/AACR2021 ★ #AACR21 ★ 20**
## Experimental and Molecular Therapeutics

### ET01 Drug Discovery
- Antibody technologies
- Biochemical modulators of the therapeutic index
- Combination chemotherapies
- Differentiation therapy
- New targets
- Novel assay technology
- Novel drug delivery systems
- Targeting the tumor microenvironment in drug development
- Other

### ET02 Mechanisms of Drug Action
- Cell cycle mechanisms of anticancer drug action
- Cellular responses to anticancer drugs
- Interactions of new agents with radiation
- Role of the microenvironment in therapeutic response
- Other

### ET03 Drug Resistance
- Drug resistance in molecular targeted therapies
- Drug transport and metabolism
- Novel mechanisms
- Regulation of gene expression in drug resistance
- Reversal of drug resistance
- Other

### ET04 Molecular Targets
- Cell death pathways and treatment
- Identification of molecular targets
- Modulation of DNA repair
- Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes
- New nonclinical models for targets
- Other

### ET05 Pharmacology, Pharmacogenetics, and Pharmacogenomics
- Cellular pharmacology
- Molecular pharmacology
- Pharmacogenetics and therapeutic response
- Pharmacogenomics
- Pharmacokinetics and pharmacodynamics
- Preclinical toxicology
- Other

### ET06 Small Molecule Therapeutic Agents
- DNA-reactive agents
- Epigenetic targets
- HDAC and methyltransferase inhibitors
- Novel antitumor agents
- Novel targets and pathways
- PI3K/AKT inhibitors
- Proteasome inhibitors
- Topoisomerases
- Tubulin agents
- Tyrosine kinase and phosphatase inhibitors
- Other

### ET07 Biological Therapeutic Agents
- (See also CL06: Immuno-oncology; ET07: Biological Therapeutic Agents)
- Antireceptors
- Apoptosis: Therapeutic manipulation
- Growth factor receptors and other surface antigens as targets for therapy
- Oncogenes, tumor suppressor genes, and gene products as targets for therapy
- Protein kinases and phosphatases as targets for therapy
- Role of microenvironment in therapeutic response
- Other

### ET08 Gene and Vector-Based Therapy
- Antisense molecules
- Gene therapy and radiation studies
- Immune modulators
- Vector systems and targeting strategies
- Other

### ET09 Preclinical Radiotherapeutics
- (See also TB09: Radiation Science; CL07: Radiation Oncology)
- Modification of radiosensitivity
- Molecular targets of radiation response
- Normal tissue/cellular stress responses to radiation
- Radioprotectors and radiosensitizers
- Radiotherapeutic combinations
- Other

## Immunology

### IM01 Tumor Immunobiology
- Adaptive immunity in tumors
- Epigenetic regulation of tumor immunity
- Inflammation and cancer: Metastasis
- Inflammation and cancer: Tumor initiation and progression
- Innate immunity to tumors
- Microbiome, inflammation, and cancer
- Novel animal models
- Oncogenic pathway-mediated regulation of inflammation and tumor immunity
- Tumor antigenicity/processing and presentation
- Tumor-induced immune suppression: Extrinsic factors
- Tumor-induced immune suppression: Intrinsic factors
- Other

### IM02 Immunotherapy, Preclinical and Clinical
- Adoptive cell therapy
- Combination immunotherapies
- Immune checkpoints
- Immune mechanisms invoked by other therapies including chemotherapy
- Immune mechanisms invoked by radiation therapy
- Immune monitoring/clinical correlates
- Immune response to therapies
- Immunomodulatory agents and interventions
- Inflammation, immunity, and cancer
- Modifiers of the tumor microenvironment
- Therapeutic antibodies, including engineered antibodies
- Vaccines (oncolytic and prophylactic)
- Other

## Clinical Trials

### CT01 Phase I Adult Clinical Trials
- (See also ET05: Pharmacology, Pharmacogenetics, and Pharmacogenomics)

### CT02 Phase II Adult Clinical Trials

### CT03 Phase III Adult Clinical Trials

### CT04 Phase I, II, or III Clinical Trials in Pediatric Cancer
- (See also CL02: Pediatric Cancer – Clinical Investigations; TB08: Pediatric Cancer – Basic Science)

### CT05 Phase I, II, or III Clinical Trials in the Elderly

### CT06 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations
### CL04 Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations
- Biobanking/biospecimen collection
- Clinical trial design
- Community engaged research/community-based participatory research
- Patient accrual and retention
- Patient navigation
- Other

### CL05 Biostatistics in Clinical Trials
- Design and analysis of clinical trials
- New study designs: Theory, methodology, and modeling
- Statistical modeling for cancer studies
- Other

### CL06 Immuno-oncology
- Adoptive cell therapy
- Combination immunotherapies
- Immune checkpoints
- Immune mechanisms invoked by other therapies including chemotherapy
- Immune mechanisms invoked by radiation therapy
- Immune monitoring/clinical correlates
- Immune response to therapies
- Immunomodulatory agents and interventions
- Inflammation, immunity, and cancer
- Modifiers of the tumor microenvironment
- Therapeutic antibodies, including engineered antibodies
- Vaccines (oncolytic and prophylactic)
- Other

### CL07 Radiation Oncology
- Clinical radiotherapeutic studies
- Interventional radiology
- Modification of radiosensitivity
- Radiation-immunotherapies and radiation-therapeutic combinations
- Radiation-induced late effects/secondary cancers
- Radiation-induced resistance
- Other

### CL08 Surgical Oncology (including Prophylactic Surgery)
- Surgical oncology

### CL09 Clinical Endocrinology
- Endocrine-related cancers
- Hormone receptors and diagnosis/prognosis
- Hormone signaling and inhibitors
- Hormone synthesis, metabolism, and inhibitors
- Neuroendocrine and other endocrine factors
- Nuclear receptors: Structure and function
- Preclinical studies of endocrine-related cancers
- Receptors and signal transduction
- Steroid hormone receptors
- Other

### CT07 Clinical Trials for COVID-19
- Phase I clinical trials in progress
- Phase II clinical trials in progress
- Phase III clinical trials in progress
- Other

### CT08 Clinical Trials in Progress
- Phase I clinical trials in progress
- Phase II clinical trials in progress
- Phase III clinical trials in progress
- Other

### CL Clinical Research
- Not including clinical trials; see also the Clinical Trials (CT) categories

### CL01 Translational Research – Molecular Biology in the Clinic
- Clinical imaging
- Cytogenetics and clinical molecular genetics
- Epigenetic therapy
- Functional and molecular imaging
- Laboratory correlates for targeted agents
- Molecular classification of tumors
- Radiomics
- Tumor staging: Correlation of clinical and molecular markers
- Other

### CL02 Pediatric Cancer – Clinical Investigations
- Adolescent and young adult oncology
- Childhood cancer drug development
- Immunotherapeutic approaches to pediatric cancer
- Pediatric cancer predisposition and surveillance
- Surveillance, late effects, and secondary cancers
- Therapeutic dosing, resistance, and combination therapy approaches in pediatric oncology
- Translational pediatric cancer research
- Other

### CL03 Clinical Research in the Elderly
- Aging, immunity, and cancer
- Other

### CL04 Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations
- Biobanking/biospecimen collection
- Clinical trial design
- Community engaged research/community-based participatory research
- Patient accrual and retention
- Patient navigation
- Other

### CL05 Biostatistics in Clinical Trials
- Design and analysis of clinical trials
- New study designs: Theory, methodology, and modeling
- Statistical modeling for cancer studies
- Other

### CL06 Immuno-oncology
- Adoptive cell therapy
- Combination immunotherapies
- Immune checkpoints
- Immune mechanisms invoked by other therapies including chemotherapy
- Immune mechanisms invoked by radiation therapy
- Immune monitoring/clinical correlates
- Immune response to therapies
- Immunomodulatory agents and interventions
- Inflammation, immunity, and cancer
- Modifiers of the tumor microenvironment
- Therapeutic antibodies, including engineered antibodies
- Vaccines (oncolytic and prophylactic)
- Other

### CL07 Radiation Oncology
- Clinical radiotherapeutic studies
- Interventional radiology
- Modification of radiosensitivity
- Radiation-immunotherapies and radiation-therapeutic combinations
- Radiation-induced late effects/secondary cancers
- Radiation-induced resistance
- Other

### CL08 Surgical Oncology (including Prophylactic Surgery)
- Surgical oncology

### CL09 Clinical Endocrinology
- Endocrine-related cancers
- Hormone receptors and diagnosis/prognosis
- Hormone signaling and inhibitors
- Hormone synthesis, metabolism, and inhibitors
- Neuroendocrine and other endocrine factors
- Nuclear receptors: Structure and function
- Preclinical studies of endocrine-related cancers
- Receptors and signal transduction
- Steroid hormone receptors
- Other

### CT07 Clinical Trials for COVID-19
- Phase I clinical trials in progress
- Phase II clinical trials in progress
- Phase III clinical trials in progress

### CT08 Clinical Trials in Progress
- Phase I clinical trials in progress
- Phase II clinical trials in progress
- Phase III clinical trials in progress

### CL Clinical Research
- Not including clinical trials; see also the Clinical Trials (CT) categories

### CL01 Translational Research – Molecular Biology in the Clinic
- Clinical imaging
- Cytogenetics and clinical molecular genetics
- Epigenetic therapy
- Functional and molecular imaging
- Laboratory correlates for targeted agents
- Molecular classification of tumors
- Radiomics
- Tumor staging: Correlation of clinical and molecular markers
- Other

### CL02 Pediatric Cancer – Clinical Investigations
- Adolescent and young adult oncology
- Childhood cancer drug development
- Immunotherapeutic approaches to pediatric cancer
- Pediatric cancer predisposition and surveillance
- Surveillance, late effects, and secondary cancers
- Therapeutic dosing, resistance, and combination therapy approaches in pediatric oncology
- Translational pediatric cancer research
- Other

### CL03 Clinical Research in the Elderly
- Aging, immunity, and cancer
- Other

### CL04 Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations
- Biobanking/biospecimen collection
- Clinical trial design
- Community engaged research/community-based participatory research
- Patient accrual and retention
- Patient navigation
- Other

### CL05 Biostatistics in Clinical Trials
- Design and analysis of clinical trials
- New study designs: Theory, methodology, and modeling
- Statistical modeling for cancer studies
- Other

### CL06 Immuno-oncology
- Adoptive cell therapy
- Combination immunotherapies
- Immune checkpoints
- Immune mechanisms invoked by other therapies including chemotherapy
- Immune mechanisms invoked by radiation therapy
- Immune monitoring/clinical correlates
- Immune response to therapies
- Immunomodulatory agents and interventions
- Inflammation, immunity, and cancer
- Modifiers of the tumor microenvironment
- Therapeutic antibodies, including engineered antibodies
- Vaccines (oncolytic and prophylactic)
- Other

### CL07 Radiation Oncology
- Clinical radiotherapeutic studies
- Interventional radiology
- Modification of radiosensitivity
- Radiation-immunotherapies and radiation-therapeutic combinations
- Radiation-induced late effects/secondary cancers
- Radiation-induced resistance
- Other

### CL08 Surgical Oncology (including Prophylactic Surgery)
- Surgical oncology

### CL09 Clinical Endocrinology
- Endocrine-related cancers
- Hormone receptors and diagnosis/prognosis
- Hormone signaling and inhibitors
- Hormone synthesis, metabolism, and inhibitors
- Neuroendocrine and other endocrine factors
- Nuclear receptors: Structure and function
- Preclinical studies of endocrine-related cancers
- Receptors and signal transduction
- Steroid hormone receptors
- Other

### CL10 Survivorship Research and Supportive Care
- Biology of cell and tissue damage
- Comparative effectiveness research and cost-effective studies
- Late effects and second cancers
- Psycho-oncology
- Supportive care, palliation, and pain management
- Translational survivorship research
- Other

### CL11 Biomarkers
- Biomarkers predictive of therapeutic benefit
- Diagnostic biomarkers
- Early detection biomarkers
- Liquid biopsies: Circulating DNA
- Liquid biopsies: Circulating tumor cells
- Metastasis biomarkers
- Prognostic biomarkers
- Other

### CL12 Clinical Outcomes Research
- Clinical outcomes research

### EN Endocrinology
- Endocrine-related cancers
- Growth factors, receptors, and signal transduction
- Hormone receptors and diagnosis/prognosis
- Hormone signaling and inhibitors
- Hormone synthesis, metabolism, and inhibitors
- Neuroendocrine and other endocrine factors
- Nuclear receptors: Structure and function
- Preclinical studies of endocrine-related cancers
- Receptors and signal transduction
- Steroid hormone receptors
- Other
**EP Epidemiology (including Genetic, Molecular, and Integrative Epidemiology)**

**EP01 Epidemiology**
- Biomarkers of endogenous or exogenous exposures, early detection, and biologic effects
- Biomarkers of prognosis
- Cancer health disparities research
- Descriptive epidemiology, covering cancer incidence, mortality, clusters, and trends
- Diet, alcohol, tobacco use, and other lifestyle risk factors
- Environmental and occupational risk factors
- Familial and hereditary cancers
- Functional studies of genetic variants
- Gene-gene and gene-environment interactions
- Genome-wide association studies (GWAS)/post-GWAS
- Health services and comparative effectiveness research
- Infection and immune factors
- Next-generation sequencing in epidemiology studies (whole genome, exome, targeted, or fine-mapping)
- Pathway and candidate gene studies of risk or prognosis
- Pharmacoepidemiology
- Preneoplastic and tumor markers
- Primary and secondary intervention studies
- Risk prediction models for incidence, prognosis, and/or mortality
- Screening and early detection
- Statistical and epidemiological methodology
- Survivorship research
- Other

**PR Prevention, Early Detection, and Interception**

**PR01 Preclinical Prevention, Early Detection, and Interception**
- Animal models in prevention
- Biological and biochemical mechanisms in prevention
- Biomarkers and intervention studies
- Cellular models
- Chemoprevention studies
- Diet, nutrition, and cancer
- Microbiome and prevention
- Molecular markers in prevention research
- Molecular targets for prevention
- New agent development
- Screening and early detection
- Other

**PR02 Clinical Prevention, Early Detection, and Interception**
- Application of molecular pathology in clinical prevention
- Biomarkers and intervention studies
- Cancer health disparities research
- Cancer surveillance and screening studies
- Chemoprevention clinical trials
- Genetic markers as surrogate endpoints in prevention trials
- Genomics and proteomics in cancer risk and response assessment
- Infections and viral-related cancers
- Microbiome and prevention
- Prevention and treatment of premalignant lesions (intraepithelial neoplasia)
- Prevention of second cancers
- Recruitment of racial and ethnic minorities and other underserved populations in clinical prevention trials
- Screening and early detection
- Other

**COVID-19 and Cancer**

**COVID01 Intersection of the Biology of SARS-CoV-2 and Cancer**
- Biomarkers/predictors of COVID-19 and cancer
- Host genomics and genetics
- Immunobiology
- Pathophysiology
- Viral evolution
- Other

**PR03 Implementation Science**
- Behavioral science and prevention
- Cancer communication and decision-making
- Cancer health disparities research
- Genetic testing and counseling
- Health policy and outcomes
- Obesity, diet, physical activity, and energy balance
- Quality of life/life effects/survivorship
- Other

**COVID02 Diagnostics for COVID-19 Testing: Design, Development, and Validation**

**COVID03 Cancer Drug Repurposing to Treat COVID-19**

**COVID04 COVID-19 Vaccine Development**

**COVID05 Effects of Cancer Immunotherapies on Patients with COVID-19 (with or without Cancer)**

**COVID06 Clinical Trials**
- [See also CT07: Clinical Trials for COVID-19 (Phase I–Phase IV and Trials in Progress)]
  - Phase I
  - Phase II
  - Phase III
  - Phase IV, observational, and expanded access clinical trials in progress

**COVID07 Continuity of Cancer Care**
- Long-term cancer outcomes
- Novel health care strategies (including telehealth and digital health)

**RSP Regulatory Science and Policy**

**RSP01 Regulatory Science and Policy**
- Biosimilars and generics
- Clinical trial design and accrual
- Combination therapies and codevelopment of investigational agents and diagnostics
- Data science and informatics
- Novel endpoints and biomarkers
- Real-world evidence and retrospective analyses
- Tobacco and e-cigarette regulation
- Other

**SHP Science and Health Policy**

**SHP01 Science and Health Policy**
- Cancer health disparities
- Cancer survivorship
- Comparative effectiveness research
- Implementation science
- Patient advocacy and engagement
- Value and cost issues in cancer care
- Other